ArticleEuropean journal of clinical pharmacology2012

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.

Paul Statkevich et al.PubMed ↗Publisher ↗

No numbers read from the abstract.